Based in Nijmegen, the Netherlands, the company started its biopharmaceutical franchise in 2007 and is building a promising portfolio of next generation medicines.

Synthon is focusing increasingly on the therapeutic areas of oncology and auto-immune diseases.

In 2015 the company recorded its turnover at $301 million.